Antibody-Drug Conjugates Beyond HER2 in Non-Small Cell Lung Cancer (NSCLC): Mechanisms, Emerging Targets, and Future Directions Review

publication date

  • May 2, 2026

webpage

published in

keywords

  • B7-H3
  • CEACAM5
  • HER3
  • MET
  • Nectin-4
  • TROP2
  • antibody-drug conjugates (ADCs)
  • biomarkers
  • non-small cell lung cancer (NSCLC)
  • toxicity management

volume

  • 16

issue

  • 5